A further challenge is the development of drug resistance, as tumor cells may escape PCD via epigenetic silencing—such as RIPK3 promoter methylation—or metabolic reprogramming, including glycolysis-driven inhibition of necroptotic signaling. The gene discussed is RIPK3; the disease is neoplasm.